Table 5.

Summary of microbiological and clinical response versus achievement of tigecycline or meropenem pharmacodynamic threshold exposure

Antibiotic	Microbiological response			Clinical response
	Eradiction	Persistance	p value	Cure	Failure	P-value
Tigecycline	n = 10	n = 2		n = 9	n = 3
fAUC/MIC ≥ 0.9	7 (70.0)	2 (100)	NC	6 (66.6)	3 (100)	NC
Meropenem	n = 4	n = 0		n = 3	n = 1
fT > MIC ≥ 40%	0	0	NC	0	0	NC
Both antibioticsa	n = 13	n = 2		n = 11	n = 4
Achieved PD threshold	7 (53.8)	2 (100)	0.486	6 (54.5)	3 (75.0)	0.604

fAUC/MIC free area under the curve/MIC, fT > MIC free time above the MIC, PD pharmacodynamic, NC not calculated

^aPatient 4 received meropenem for study days 1–4, followed by tigecycline for study days 4–14; this patient is counted as exposure threshold achieved due to attainment of tigecycline PD target